News | June 26, 2018

Thermo Fisher Scientific Launches Quick To Clinic™ Program For Biologics

Source: Patheon, part of Thermo Fisher Scientific
Contact The Supplier
Biopharma_QuickClinic_Bioreact.jpg

Clients routinely have expressed the overwhelming need to get to the First-in-Human (Phase I) clinical trials as quickly as possible to generate safety for the IND submission. Several factors are behind this need, including discovery of much-needed innovative therapies, intense completion among developers in areas such as oncology, the need for small startups to reach the next milestone quickly in order to secure additional funding and more.

Recognizing this need, Pharma Services has recently introduced its Quick to Clinic™ program for biologics drug development. This program is Fast, Flexible and Full.

How it works:

  • Fast: clients can expect released drug substance in a little as 12 months
  • Flexible: Pharma Services can work with the client’s cell line or can use the Thermo Fisher Scientific Gibco™ Freedom™ CHO-S™ platform and media. The Freedom CHO-S platform licensing agreement does not involve royalties, annual maintenance fees, or restrictions when a client sells the therapy
  • Full: The program can deliver released drug product in an additional 2 months, provides some process development work, provides some formulation development work and delivers a complete documentation package

More information on Quick to Clinic™ can be found here.

SOURCE: Patheon, part of Thermo Fisher Scientific

Patheon, part of Thermo Fisher Scientific